Another etanercept biosimilar approved for arthritic conditions

The biosimilar brand of etanercept Rymti, Etera has been approved by the TGA for use in conditions including rheumatoid arthritis, psoriatic arthritis and non-radiographic axial spondyloarthritis. The TNF inhibitor, marketed by Lupin Australia is indicated for the treatment of RA, PsA, nr-AxSpa, ankylosing spondylitis, juvenile idiopathic arthritis and plaque psoriasis. It is a biosimilar for ...

Already a member?

Login to keep reading.

© 2021 the limbic